-- Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas-- Junshi will continue to be responsible for the promotion of other indications in core areas--The companies will continue to explore business collaborations in overseas markets including emerging markets

Visit link:
Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *